Fecal Microbiota Transplantation Might Prevent Clostridioides difficile infection in IBD Patients

Clostridioides (formerly Clostridium) difficile is a Gram-positive, anaerobic, spore-forming opportunistic pathogen and is the leading cause of hospital-acquired, antibiotic-associated diarrhea. A recent study suggests that fecal microbiota transplantation (FMT) appears to be a highly effective therapy for preventing recurrent Clostridioides difficile infection (CDI) in patients with inflammatory bowel disease (IBD).
The study findings were published in the Journal of Clinical Gastroenterology on December 06, 2021.
Studies have shown that FMT is a safe and effective therapy for recurrent Clostridioides difficile infection. However, data on FMT for CDI in patients with underlying IBD are emerging but conflicting. Therefore, Dr Sahil Khanna and his team conducted a study to evaluate the efficacy and safety of FMT for CDI in IBD and its impact on IBD outcomes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.